OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kulke on Emerging Cabozantinib Data for NETs

February 1st 2018

Matthew H. Kulke, MD, Dana-Farber Cancer Institute, discusses the emerging data seen with cabozantinib (Cabometyx) for patients with neuroendocrine tumors (NETs).

Dr. Tam Discusses the DUO Trial for CLL

February 1st 2018

Constantine S. Tam, MD, associate professor, Peter MacCallum Cancer Centre, discusses, the randomized phase III DUO trial of duvelisib versus ofatumumab (Arzerra) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Dr. Sequist Distinguishes Osimertinib From Earlier NSCLC TKIs

February 1st 2018

Lecia V. Sequist, MD, associate professor of medicine, Harvard Medical School, Mary B. Saltonstall Chair, Oncology, Massachusetts General Hospital Center, discusses the tolerability of a new third-generation T790-specific inhibitor, osimertinib (Tagrisso).

Dr. Ramirez Discusses Treating Patients With NETs of the Lung

January 31st 2018

Robert Ramirez, DO, FACP, Ochsner Medical Center, discusses treating patients with neuroendocrine tumors (NETs) of the lung.

Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic Malignancies

January 31st 2018

Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

Developing Treatment for Invasive Lobular Carcinoma

January 31st 2018

Steffi Oesterreich, PhD, professor and vice chair of Precision and Translational Pharmacology, University of Pittsburgh, discusses developing treatment for patients with invasive lobular carcinoma (ILC).

Dr. Raz on the Impact of the ALCHEMIST Trial on the Treatment of Patients With Lung Cancer

January 31st 2018

Dan J. Raz, MD, MAS, co-director, Lung Cancer and Thoracic Oncology Program, assistant professor, Division of Thoracic Surgery, Department of Surgery, City of Hope, discusses the subsets of the ALCHEMIST trial.

Dr. Kim on the Safety of Immune Checkpoint Inhibition in Surgical Patients With Lung Cancer

January 31st 2018

Jae Y. Kim, MD, chief, Division of Thoracic Surgery, Department of Surgery, assistant professor, Department of Surgery, City of Hope, discusses the use of immune checkpoint inhibitors in surgical patients with lung cancer.

Dr. Bardia on Sacituzumab Govitecan in Triple-Negative Breast Cancer

January 31st 2018

Aditya Bardia, MD, MPH, assistant professor of medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses a trial investigating sacituzumab govitecan for patients with triple-negative breast cancer (TNBC).

Dr. Oh on Abiraterone Versus Docetaxel in Prostate Cancer

January 31st 2018

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai Hospital, discusses the abiraterone acetate (Zytiga) versus docetaxel for patients with prostate cancer.

Dr. Perales on Treatment With Approved CAR T-Cell Therapy

January 31st 2018

Miguel-Angel Perales, MD, Deputy Chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses determining which chimeric antigen receptor (CAR) T-cell therapy to use for patients with hematologic malignancies.

Dr. Massarelli on First-Line ALK+ NSCLC Treatment

January 30th 2018

Erminia Massarelli, MD, PhD, MS, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses the adoption of alectinib (Alecensa) as the first-line therapy in the treatment of patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

January 30th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

Dr. Kardosh Discusses Epacadostat in Gastric/GEJ Adenocarcinoma

January 30th 2018

Adel Kardosh, MD, postdoctoral medical fellow, oncology, Stanford Medicine, discusses epacadostat in gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Dr. Carey Discusses the CALGB40502 Trial in TNBC

January 30th 2018

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses the CALGB 40502/NCCTG N063H trial in patients with triple-negative breast cancer (TNBC).

Dr. Wise on the Development of Precision Medicine in Prostate Cancer

January 30th 2018

David R. Wise, MD, PhD, assistant professor, Department of Medicine, assistant professor, Department of Urology, NYU Langone’s Perlmutter Cancer Center, discusses ongoing trials at NYU that are investigating precision oncology hypotheses.

Dr. King on Role of Sentinel Lymph Node Biopsy in Breast Cancer

January 30th 2018

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Women’s Cancer Center, discusses the role of sentinel lymph node biopsy in breast cancer.

Dr. Zhu Discusses Findings of the KEYNOTE-224 in HCC

January 30th 2018

Andrew Zhu, MD, PhD, director, Liver Cancer Research, Medicine, Massachusetts General Hospital, discusses the findings of KEYNOTE-224 in hepatocellular carcinoma (HCC).

Dr. Skarbnik on Impact of Checkpoint Inhibition Following ASCT

January 30th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.

Dr. Balar on Current and Future Standards of Care in Kidney Cancer Treatment

January 30th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the potential of existing targeted therapy coupled with immunotherapy to improve overall survival (OS) in patients with kidney cancer.